February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 23, 2026

Hypertension: Biomarkers Clarify Heart Failure Risk

Cardiac biomarkers help stratify heart failure risk among patients with prediabetes and hypertension.

Conexiant

February 19, 2026

BP Targets Across CKM Stages

Investigators assess stage-specific outcomes, safety, and net benefit of intensive blood pressure control in cardiovascular-kidney-metabolic syndrome.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 18, 2026

Weight Regain Rapidly Follows GLP-1 Cessation

Systematic review finds most lost weight returns within two years of stopping weight management medication

Conexiant

February 17, 2026

Statin Side Effects Largely Unsupported by Trial Data

Most adverse effects listed on drug labels lack causal evidence, meta-analysis finds

Conexiant

February 16, 2026

Intermittent Fasting Shows No Edge Over Standard Diets

Cochrane review finds the approach produces similar weight loss and quality-of-life outcomes compared with conventional calorie restriction

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

February 12, 2026

Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

Conexiant